Jose Barrueco

Jose Barrueco

UNVERIFIED PROFILE

Are you Jose Barrueco?   Register this Author

Register author
Jose Barrueco

Jose Barrueco

Publications by authors named "Jose Barrueco"

Are you Jose Barrueco?   Register this Author

13Publications

557Reads

7Profile Views

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Future Oncol 2019 Apr 13;15(12):1363-1383. Epub 2019 Feb 13.

Boehringer Ingelheim Pharma GmbH & Co, KG, Germany & Institute of Pharmacology, Johannes Gutenberg-University Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0948DOI Listing
April 2019

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

J Clin Oncol 2017 Nov 11;35(31):3591-3600. Epub 2017 Sep 11.

Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.9012DOI Listing
November 2017

Response to 'Dai W et al. Am J Cancer Res 2015;5(10):3270-3275' from the makers of nintedanib.

Am J Cancer Res 2016 1;6(7):1547-8. Epub 2016 Jul 1.

Boehringer Ingelheim Pharmaceuticals Ridgefield, CT, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969403PMC
August 2016

BIBF1120 (Vargatef) Inhibits Preretinal Neovascularization and Enhances Normal Vascularization in a Model of Vasoproliferative Retinopathy.

Invest Ophthalmol Vis Sci 2015 Dec;56(13):7897-907

Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Center, Université de Montréal, Montréal, Quebec, Canada 2Department of Pediatrics, Ophthalmology and Pharmacology, Centre Hospitalier Universitaire Sainte-Justine Research Center, Univer.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1167/iovs.15-17146DOI Listing
December 2015